Last reviewed · How we verify
18F-FET
18F-FET is a positron-emitting radiopharmaceutical used for imaging of gliomas and other brain tumors.
18F-FET is a positron-emitting radiopharmaceutical used for imaging of gliomas and other brain tumors. Used for Imaging of gliomas and other brain tumors.
At a glance
| Generic name | 18F-FET |
|---|---|
| Also known as | 18F-Fluoroethyltyrosine, PET/CT |
| Sponsor | Marcelo F. Di Carli, MD, FACC |
| Target | Amino acid transport system L |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the amino acid transport system L, allowing for visualization of tumor cells in the brain. This is particularly useful for diagnosing and monitoring the progression of gliomas.
Approved indications
- Imaging of gliomas and other brain tumors
Common side effects
Key clinical trials
- 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging (NA)
- Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms (PHASE2)
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
- Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas (PHASE1)
- [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
- Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET (NA)
- Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
- 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-FET CI brief — competitive landscape report
- 18F-FET updates RSS · CI watch RSS
- Marcelo F. Di Carli, MD, FACC portfolio CI